Amazon’s Cloud Is Printing Money. The Question Is What It Costs to Keep Going.
According to post-earnings coverage, sell-side analysts at multiple firms raised their price targets following Amazon's Q2 2026 results on July...
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
According to post-earnings coverage, sell-side analysts at multiple firms raised their price targets following Amazon's Q2 2026 results on July...
Three years ago, Microsoft was a mature software giant with respectable but predictable margins, a cloud business growing fast enough...
The standing BullScope yardsticks for Walmart, computed from official filings and refreshed with each new edition.
In one breath Walmart's filed numbers show a business earning more from each dollar of sales than at any point...
In one breath The BEA's advance estimate for Q2 2026, released July 30, shows the economy growing at 1.5% annually,...
In one breath Meta's revenue is growing faster than almost anyone expected. Its profit, for this quarter, is not. The...
The standing BullScope yardsticks for Tesla, computed from official filings and refreshed with each new edition.
In 2009, Visa was barely a public company, freshly listed after decades as a bank-owned cooperative. It had a simple...
One number stops the conversation cold. Tesla's current P/E ratio, the price a buyer pays per dollar of annual profit,...
The standing BullScope yardsticks for NVIDIA, computed from official filings and refreshed with each new edition.
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer